149MO Irpagratinib (ABSK-011) plus atezolizumab in first-line (1L) and immune checkpoint inhibitors (ICIs) treated advanced hepatocellular carcinoma (HCC) with FGF19 overexpression (+): Updated results of the phase II ABSK-011-201 study
Titel:
149MO Irpagratinib (ABSK-011) plus atezolizumab in first-line (1L) and immune checkpoint inhibitors (ICIs) treated advanced hepatocellular carcinoma (HCC) with FGF19 overexpression (+): Updated results of the phase II ABSK-011-201 study
Auteur:
Cheng, Q. Zhang, Y. Wang, J. Zhao, L. Hou, C. Cai, J. Qin, Y. Liang, T. Feng, X. Zuo, Q. Wu, Q. Li, H. Chen, X-P.